Impact of salt restriction on renal function, urine protein–creatinine ratio and nutrition of patients with chronic kidney disease stages III–V

Abstract Background Chronic kidney disease (CKD) are associated with acute myocardial infarction (AMI). High-sensitive cardiac troponin (hs-cTn) has been evidenced to enhance the early diagnostic accuracy of AMI, but hs-cTn levels are often chronically elevated in CKD patients, which reduces their diagnostic utility. The aim of this study was to derive optimal cutoff-values of hs-cTn levels in patients with CKD and suspected AMI. Methods In this retrospective paper, a total of 3295 patients with chest pain (2758 in AMI group and 537 in Non-AMI group) were recruited, of whom 23.1% were had an estimated glomerular filtration rate (eGFR) of < 60 mL min−1 (1.73 m2)−1. Hs-cTnI values were measured at presentation. Results AMI was diagnosed in 83.7% of all patients. The optimal value of hs-TnI in diagnosing AMI was 1.15 ng mL−1, which were higher in males than females comparing different cutoff-values of subgroups divided by age, gender and renal function, and which increased monotonically with decreasing of eGFR because in patients with CKD without AMI, the correlation between hs-cTnI and renal function is low but significant (r2 = 0.067, P < 0.001). Conclusions Different optimal cutoff-values of hs-cTnI in the diagnosis of AMI in patients with CKD were helpful to the clinical diagnosis of AMI in various populations and were higher in males than females, but which was needed to be validated by multicenter randomized controlled clinical studies in the future.

Download Full-text

The Search for a New Marker of Renal Function in Older Patients with Chronic Kidney Disease Stages 3–4: Usefulness of Cystatin C-Based Equations

Nephron Clinical Practice ◽

10.1159/000214212 ◽

2009 ◽

Vol 112 (3) ◽

pp. c164-c170 ◽

Cited By ~ 6

Author(s):

Néstor Fontseré ◽

Vicens Esteve ◽

Ana Saurina ◽

Mónica Pou ◽

Nuria Barba ◽

...

Keyword(s):

Chronic Kidney Disease ◽

Renal Function ◽

Kidney Disease ◽

Cystatin C ◽

Older Patients ◽

Disease Stages

Download Full-text

Aortic Stiffness Is Independently Associated With Rate of Renal Function Decline in Chronic Kidney Disease Stages 3 and 4

Hypertension ◽

10.1161/hypertensionaha.109.143024 ◽

2010 ◽

Vol 55 (5) ◽

pp. 1110-1115 ◽

Cited By ~ 120

Author(s):

Martin L. Ford ◽

Laurie A. Tomlinson ◽

Thomas P.E. Chapman ◽

Chakravarthi Rajkumar ◽

Stephen G. Holt

Keyword(s):

Chronic Kidney Disease ◽

Renal Function ◽

Kidney Disease ◽

Aortic Stiffness ◽

Renal Function Decline ◽

Disease Stages

Download Full-text

Impact of sodium–glucose cotransporter 2 inhibitors on renal function in participants with type 2 diabetes and chronic kidney disease with normoalbuminuria

Diabetology & Metabolic Syndrome ◽

10.1186/s13098-020-0516-9 ◽

2020 ◽

Vol 12 (1) ◽

Cited By ~ 4

Author(s):

Akinobu Nakamura ◽

Hideaki Miyoshi ◽

Hiraku Kameda ◽

Kumiko Yamashita ◽

Yoshio Kurihara

Keyword(s):

Type 2 Diabetes ◽

Chronic Kidney Disease ◽

Renal Function ◽

Kidney Disease ◽

Sglt2 Inhibitor ◽

Sglt2 Inhibitors ◽

Creatinine Ratio ◽

Sodium Glucose Cotransporter ◽

Clinical Records

Abstract Background We compared the effects of sodium–glucose cotransporter 2 (SGLT2) inhibitors on renal function in participants with type 2 diabetes and chronic kidney disease (CKD) classified by degree of albuminuria. Methods A retrospective review of the clinical records of Japanese participants with type 2 diabetes (age > 20 years; SGLT2 inhibitor treatment > 2 years; estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73 m2) was conducted. Based on the urinary albumin-to-creatinine ratio (UACR) or urinary protein-to-creatinine ratio (UPCR) at the start of SGLT2 inhibitor administration, participants were categorized into three groups: normoalbuminuria (A1; UACR < 30 mg/g Cr or UPCR < 0.15 g/g Cr), microalbuminuria (A2; UACR 30 to < 300 mg/g Cr or UPCR 0.15 to < 0.50 g/g Cr), and macroalbuminuria (A3; UACR ≥ 300 mg/g Cr or UPCR ≥ 0.50 g/g Cr). The study outcome was a comparison of the rates of change in renal function evaluated by eGFR at 2 years after starting SGLT2 inhibitor among the three groups. Results A total of 87 participants (40 females, 47 males) were categorized into three groups: A1 (n = 46), A2 (n = 25), and A3 (n = 16). eGFR was similarly decreased at 2 years before starting SGLT2 inhibitor in all three groups. However, the decline in eGFR was ameliorated at 2 years after starting SGLT2 inhibitor, and eGFR was rather increased in the A1 and A2 groups. Interestingly, the rate of change in eGFR at 2 years after starting SGLT2 inhibitor in the A1 group was significantly higher than that in the A3 group. Conclusions These results demonstrate that more favorable effects of SGLT2 inhibitors on renal function were observed in participants with type 2 diabetes and CKD with normoalbuminuria compared with those with macroalbuminuria. Trial registration UMIN-CTR: UMIN000035263. Registered 15 December 2018

Download Full-text

The Efficacy of Adipose-Derived Stem Cells (ADSCs) on Chronic Kidney Disease in Dogs

Nanoscience and Nanotechnology Letters ◽

10.1166/nnl.2019.3056 ◽

2019 ◽

Vol 11 (12) ◽

pp. 1724-1728

Author(s):

Mengling Zhu ◽

Xiaoyun Lai ◽

Yixin Wen ◽

Haibin Zhang

Keyword(s):

Chronic Kidney Disease ◽

Renal Function ◽

Treatment Group ◽

Kidney Disease ◽

Adipose Derived Stem Cells ◽

Tubular Epithelial Cells ◽

Renal Tubular Epithelial Cells ◽

Urine Protein ◽

Treatment Groups ◽

Renal Tubular

To investigate the therapeutic effect of adipose-derived stem cells (ADSCs) on chronic kidney disease (CKD) in dogs, blood routine examination, urine protein quantitative test, renal function test, urine sediment staining microscopy and B-ultrasonic test of kidney were used to compare the treatment of chronic kidney disease in dogs treated with three different therapies (NT treatment group: traditional supportive therapy group; MT1 treatment group: ADSCs treatment group; MT2 treatment group: NT mixed MT1 treatment group). Results showed that the numbers of red blood cells (RBC), hemoglobin (HGB) and hematocrit (HCT) in MT1 and MT2 treatment groups were higher than those in the NT group, and the urine protein excretion and the levels of serum urea and creatinine in MT1 and MT2 treatment groups were lower than those in the NT treatment group. Besides, there was no further deterioration of kidney morphology in MT1 and MT2 treatment groups. However, a large number of renal tubular epithelial cells and epithelial casts were observed in NT treatment group, while only a small number of renal tubular epithelial cells were observed in MT1 and MT2 treatment groups, indicating the intravenous injection of ADSCs can significantly improve the physical signs and renal function of dogs with CKD, and combined with the traditional therapy, ADSCs has a good prospect for the treatment of CKD in dogs.

Download Full-text